{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:25:16Z","timestamp":1789010716286,"version":"build-2803163510"},"reference-count":35,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","license":[{"start":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:00:00Z","timestamp":1525996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">5\u2010Fluorouracil (5\u2010FU) and capecitabine\u2010associated cardiotoxicity ranging from asymptomatic electrocardiography (ECG) abnormalities to severe myocardial infarction has been reported in a number of studies, but such cardiotoxicity in Chinese patients with malignant diseases has not been investigated to date. In the present study, we aimed to prospectively evaluate the incidence rates and clinical manifestations of 5\u2010FU\u2010 and capecitabine\u2010associated cardiotoxicity in cancer patients recruited from multiple centers in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">Among the 527 patients who completed the study, 196 received 5\u2010FU\u2010based chemotherapy and 331 received capecitabine\u2010based chemotherapy as either first\u2010line or adjuvant therapy. Adverse events were reported during the treatment and up to 28 days of follow\u2010up. Outcome measures included ECG, myocardial enzymes, cardiac troponin, brain natriuretic peptide and echocardiography. Univariate analysis and logistic regression were performed for subgroup analysis and identification of significant independent variables that are associated with cardiotoxicity of both agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      In total, 161 of 527 patients (30.6%) experienced cardiotoxicity. The incidence rate of cardiotoxicity was 33.8% (112\/331) in the capecitabine group, which was significantly higher than the rate of 25% (49\/196) in the 5\u2010FU group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0042). 110\/527 patients (20.9%) suffered arrhythmia, 105\/527 (19.9%) developed ischemic changes, while only 20\/527 patients (3.8%) presented heart failure and 6\/527 patients (1.1%) had myocardial infarction. Pre\u2010existing cardiac disease, hypertension, capecitabine\u2010based chemotherapy and duration of treatment were identified as significant risk factors associated with cardiotoxicity. The odds ratio were 15.7 (prior history of cardiac disease versus no history), 1.86 (capecitabine versus 5\u2010FU), 1.06 (5\u20138 versus 1\u20134 chemotherapy cycles) and 1.58 (hypertension versus no hypertension), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Cardiotoxicity induced by fluoropyrimidines in the Chinese population may be underestimated in clinical practice. Close monitoring of patients is recommended, especially for those patients at high risk for cardiotoxicity. Possible risk factors are duration of treatment, capecitabine\u2010based chemotherapy, pre\u2010existing cardiac diseases and hypertension.<\/jats:p>\n                    <jats:p xml:lang=\"en\">\n                      <jats:italic toggle=\"yes\">Trial registration<\/jats:italic>\n                      This study was initiated on January 22, 2014 and has been retrospectively registered with the registration number ChiCTR1800015434\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40880-018-0292-1","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T10:06:32Z","timestamp":1526033192000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Cardiotoxicity of 5\u2010fluorouracil and capecitabine in Chinese patients: a prospective study"],"prefix":"10.34133","volume":"38","author":[{"given":"Jianjun","family":"Peng","sequence":"first","affiliation":[{"name":"First Affiliated Hospital of Sun Yat\u2010sen University","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Dong","sequence":"additional","affiliation":[{"name":"The 3rd Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital","place":["Kunming, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["Changchun, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Li","sequence":"additional","affiliation":[{"name":"Fujian Provincial Hospital","place":["Fuzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[{"name":"Nanjing Medical University","place":["Nanjing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Jiaotong University","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhao","sequence":"additional","affiliation":[{"name":"the Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province","place":["Shijiazhuang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[{"name":"Xinqiao Hospital of Third Military Medical University","place":["Chongqing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Ruijin Hospital","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Li","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Kunming Medical University","place":["Kunming, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Wang","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[{"name":"The first Affiliated Hospital of Bengbu Medical College","place":["Bengbu, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Zhejiang University School of Medicine","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Sichuan University","place":["Chengdu, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Chen","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010sen University Cancer Center","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"e_1_3_2_2_2","first-page":"126","article-title":"Cardio\u2010oncology: a new medical issue","volume":"2","author":"Cardinale D","year":"2008","unstructured":"Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Cardio\u2010oncology: a new medical issue. Ecancermedicalscience. 2008; 2: 1263234071","journal-title":"Ecancermedicalscience"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.301"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2282"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330902733961"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000072334"},{"issue":"6","key":"e_1_3_2_7_2","first-page":"PI51","article-title":"Cardiotoxicity following different doses and schedules of 5\u2010fluorouracil administration for malignancy\u2014a survey of 427 patients","volume":"8","author":"Tsavaris N","year":"2002","unstructured":"Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, et al. Cardiotoxicity following different doses and schedules of 5\u2010fluorouracil administration for malignancy\u2014a survey of 427 patients. Med Sci Monit. 2002; 8 (6): PI51\u2013PI57.","journal-title":"Med Sci Monit"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000331645"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432\u2010007\u20100250\u20109"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010005\u20100178\u20101"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.03.005"},{"issue":"5","key":"e_1_3_2_12_2","first-page":"430","article-title":"A retrospective study of cardiotoxicities induced by 5\u2010fluouracil (5\u2010FU) and 5\u2010FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center","volume":"62","author":"Khan MA","year":"2012","unstructured":"Khan MA, Masood N, Husain N, Ahmad B, Aziz T, Naeem A. A retrospective study of cardiotoxicities induced by 5\u2010fluouracil (5\u2010FU) and 5\u2010FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc. 2012; 62 (5): 430\u2013434.","journal-title":"J Pak Med Assoc."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.509"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.1990.11739029"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167\u20108140(88)90296\u20104"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.4.1296"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000227226"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097\u20100142(19931001)72:7<2242::AID\u2010CNCR2820720730>3.0.CO;2\u2010E"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/030089168206800609"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf108"},{"issue":"13","key":"e_1_3_2_21_2","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5\u2010fluorouracil chemotherapy is due to protein kinase C\u2010mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri M","year":"1993","unstructured":"Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5\u2010fluorouracil chemotherapy is due to protein kinase C\u2010mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993; 53 (13): 3028\u20133033.","journal-title":"Cancer Res."},{"issue":"2","key":"e_1_3_2_22_2","first-page":"81","article-title":"Endothelin\u20101 and 5\u2010fluorouracil\u2010induced cardiotoxicity","volume":"45","author":"Porta C","year":"1998","unstructured":"Porta C, Moroni M, Ferrari S, Nastasi G. Endothelin\u20101 and 5\u2010fluorouracil\u2010induced cardiotoxicity. Neoplasma. 1998; 45 (2): 81\u201382.","journal-title":"Neoplasma"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.2012.0084"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2012.09.003"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601224"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt479"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.03.004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008369629944"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000371"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds236"},{"key":"e_1_3_2_31_2","unstructured":"National Institute for Health and Care Excellence (NICE) : Managing advanced and metastatic colorectal cancer. 2017. https:\/\/pathways.nice.org.uk\/pathways\/colorectal\u2010cancer\/managing\u2010advanced\u2010and\u2010metastatic\u2010colorectal\u2010cancer. Accessed 27 Mar 2018"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20005.14.589"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010800"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2943"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094\u2010012\u20100843\u2010x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495\u2010199855030\u201000012"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-018-0292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40880-018-0292-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1186%2Fs40880-018-0292-1","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40880-018-0292-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1186\/s40880-018-0292-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:57:55Z","timestamp":1773824275000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1186\/s40880-018-0292-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1186\/s40880-018-0292-1"],"URL":"https:\/\/doi.org\/10.1186\/s40880-018-0292-1","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]},"assertion":[{"value":"2017-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"22"}}